 Braxia Scientific Corp has said that its clinical research and development team will commence a randomized clinical trial RCT targeting treatment-resistant depression using psilocybin. The Toronto-based company said the trial is the latest step as it develops the next generation of novel psychedelic treatments and delivery systems through its network of clinics. 